Literature DB >> 19615795

Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck.

Fa-Yu Liu1, Zhen-Jin Zhao, Peng Li, Xue Ding, Zhi-Hong Zong, Chang-Fu Sun.   

Abstract

Metastatic squamous cell carcinoma (SCC) of the head and neck expresses chemokine receptor 7 (CCR7), which activates phosphoinositide-3 kinase (PI3K) to promote invasion and survival of SCC cells in the head and neck. We hypothesised that mammalian target of rapamycin (mTOR) may be the downstream molecule of the CCR7-PI3K pathway. Results have shown that interaction between CCR7 and its ligand CCL19 induces the phosphorylation of mTOR and its target p70s6k. This phosphorylation is abolished by inhibition of CCR7 and PI3K/Akt, indicating that mTOR is involved in the CCR7-PI3K cascade. The inhibitors of mTOR and CCR7-PI3K also lead to a significant increase in CCL19-induced death, apoptosis, and cell-cycle arrest of metastatic SCC cells in the head and neck. Taken together, our data indicate the important part played by mTOR in CCR7-induced survival of such SCC cells. Copyright 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19615795     DOI: 10.1016/j.bjoms.2009.06.007

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  18 in total

Review 1.  Chemopreventive potential of natural compounds in head and neck cancer.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Dong M Shin
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  PKCα take part in CCR7/NF-κB autocrine signaling loop in CCR7-positive squamous cell carcinoma of head and neck.

Authors:  Zhao Zhen-jin; Li Peng; Liu Fa-yu; Sun Liyan; Sun Chang-fu
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

3.  Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.

Authors:  Dong Hoon Shin; Hye-Young Min; Adel K El-Naggar; Scott M Lippman; Bonnie Glisson; Ho-Young Lee
Journal:  Mol Cancer Ther       Date:  2011-10-06       Impact factor: 6.261

4.  CC-chemokine receptor 7 is overexpressed and correlates with growth and metastasis in prostate cancer.

Authors:  Yongqian Chen; Ye Tian; Zhengguo Ji; Zhi Liu; Donghao Shang
Journal:  Tumour Biol       Date:  2015-02-15

5.  Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.

Authors:  Tomofumi Naruse; Souichi Yanamoto; Shin-ichi Yamada; Satoshi Rokutanda; Akiko Kawakita; Goro Kawasaki; Masahiro Umeda
Journal:  Pathol Oncol Res       Date:  2015-02-15       Impact factor: 3.201

6.  Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

Authors:  Gautam Prasad; Theo Sottero; Xiaodong Yang; Sabine Mueller; C David James; William A Weiss; Mei-Yin Polley; Tomoko Ozawa; Mitchel S Berger; Dana T Aftab; Michael D Prados; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2011-02-11       Impact factor: 12.300

7.  Selective abrogation of BiP/GRP78 blunts activation of NF-κB through the ATF6 branch of the UPR: involvement of C/EBPβ and mTOR-dependent dephosphorylation of Akt.

Authors:  Shotaro Nakajima; Nobuhiko Hiramatsu; Kunihiro Hayakawa; Yukinori Saito; Hironori Kato; Tao Huang; Jian Yao; Adrienne W Paton; James C Paton; Masanori Kitamura
Journal:  Mol Cell Biol       Date:  2011-02-07       Impact factor: 4.272

Review 8.  Does CCL19 act as a double-edged sword in cancer development?

Authors:  Arezoo Gowhari Shabgah; Zaid Mahdi Jaber Al-Obaidi; Heshu Sulaiman Rahman; Walid Kamal Abdelbasset; Wanich Suksatan; Dmitry O Bokov; Lakshmi Thangavelu; Abduladheem Turki Jalil; Farhad Jadidi-Niaragh; Hamed Mohammadi; Kazem Mashayekhi; Jamshid Gholizadeh Navashenaq
Journal:  Clin Exp Immunol       Date:  2022-04-04       Impact factor: 4.330

Review 9.  C-C Chemokine Receptor 7 in Cancer.

Authors:  Colin A Bill; Christopher M Allen; Charlotte M Vines
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

10.  CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells.

Authors:  Ying Xu; Lifeng Liu; Xueshan Qiu; Lili Jiang; Bo Huang; Haiying Li; Zixuan Li; Wenting Luo; Enhua Wang
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.